Atinvicitinib

Overview

Atinvicitinib is an orally active and selective JAK1 inhibitor. Atinvicitinib blocks signaling of JAK1 -dependent pruritogenic and pro-inflammatory cytokines, including those in the IL-31 , IL-4 , and IL-13 pathways. Atinvicitinib can be used for the researches of pruritus associated with allergic dermatitis and canine atopic dermatitis.

Application

Products | Products > Disease Areas > Allergy | Products > Disease Areas > Skin Inflammation | Products > Disease Areas > Atopic Dermatitis | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Epigenetics | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > JAK | Products > Signaling Pathways > Interleukin Related

Product Information

• Catalog No.: HY-145551
• CAS No.: 2169273-59-8
• Molecular Formula: C16H17FN6O3
• Molecular Weight: 360.34
• Purity: 98.62%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: 2.5 mg/mL (6.94 mM); Clear solution; Need ultrasonic
• Availability: In-stock

Source

Original product source